Remember the quote by Mark Twain, “Quitting smoking is easy, I’ve done it hundreds of times”. Different studies found, about 70 percent smokers who decide to quit smoking, fails within their first week. However, the smoking rates have significantly fallen is the Unites States since the 190s, when smoking was at the pick and now there are around 42 million smokers including the teenagers and young adults in the US. A total of $200 billion is spent annually all over the world for tobacco consumption and related health care costs. Not only the money, around 6 million people lost their life due to smoking and related diseases worldwide. So, this topic has a great demand for scientists to discover new and improved treatment methods for smokers.
A recent study found a new pattern for quitting tobacco, which aid is the best for the success at quitting tobacco? Can be predicted from the way a smoker’s body processes nicotine or from his metabolism process. Although, some study was conducted in the past to examine the relationship between metabolism and smoking cessation treatments, but the metabolisms of individuals were not tested before the individuals were randomly assigned to treatments in these studies. Also, no previous studies examined varenicline as a newer cessation medication.
This recent study is a multi-center alliance by researchers from the Centre for Addiction and Health at the University of Toronto, Canada, the State University of New York at Buffalo, NY, the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and The University of Texas MD Anderson Cancer Center in Houston.
The research outcome of the research based on smokers metabolism process, up to 60 percent of the smokers are normalized metabolizers, while the rest are slow metabolizers and also found that it might be better off using a medicine than nicotine patches. Also, experts argued the cost-effectiveness of these extra tests would need to be determined. The outcomes of the research purported to be the first of its kind and published in The Lancet Respiratory Medicine.
To compare the efficiency of nicotine patches or the drug varenicline, the researcher took a sample of 1,246 people who want to quit smoking and seeking treatment from the above four medical centers. Examining the metabolisms of the participants, the researchers divided the participants into two groups, among them 662 participants were slow metabolizers and 584 were considered to be normal metabolizers.
From the University of Pennsylvania, US, Professor Caryn Lerman, who co-led the research published in the journal that, “As many as 65 percent of smokers who try to quit relapse within the first week”.